Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Biotechnology

Healthcare
$3.50 +0.57%

+$0.03 today

Market cap
$555.14M
Beta
0.80
P/E (TTM)
-8.2
EPS (TTM)
-$0.54
52W Low $1.34High $5.15

Volume 2.94M

Average 1.40M

ACRS Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Aclaris Therapeutics, Inc.NASDAQ: ACRS

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $6.74M rose 9.8% year over year, ahead of the +5.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 20.9% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.

Context

  • Selling, general & admin amounted to 280.8% of revenue in FY2025, up 162.2 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 7 analysts of $11.89M (-45.9%) for the fiscal year ending Dec 2026, a slowdown from the -1.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.74M+20.9% QoQ
Last fiscal yearDec 2025
$21.97M-1.0% YoY
LTMMar 2026
$22.58M+5.5% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.8%-52.1%-61.9 pp
1 year-1.0%-45.9%-44.9 pp
3-year CAGR-4.4%-18.1%-13.7 pp
5-year CAGR+47.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
21.97M USD
Year-over-year change
-1.0%
4-year CAGR
-1.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ACRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +5.5% is the 9th highest of 10, against a peer median of +37.0%.
  • Selling, general & admin amounts to 269.8% of revenue for ACRS, versus a peer median of 1022.9%.
ACRS Competitors
Selling, General & Admin for ACRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$1.14T USD+9732467.6%-14.5%—
ALMSAlumis Inc. Common StockLTM Jun 2026$77.08M USD+17.2%+94.2%1041.9%
ANABAnaptysBio, Inc.LTM Mar 2026$62.81M USD+42.2%+11.5%27.0%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$46.46M USD+34.5%+22.2%—
TRAXFirst Tracks Biotherapeutics IncFY2025$39.39M USD+37.0%——
IMUXImmunic, Inc.LTM Mar 2026$23.53M USD+30.1%+11.7%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$22.58M USD+5.5%-4.4%269.8%
IFRXInflaRx N.V.LTM Mar 2026€14.24M EUR-27.6%+7.0%48538.7%
ATTOAttovia Therapeutics, Inc.FY2025$13.55M USD+83.7%—1003.9%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€9.82M EUR+63.8%——
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ACRS) —+37.0%+11.6%1022.9%

Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.76M29.75M31.25M18.72M7.83M
Cost of Revenue4.71M11.96M18.08M2.79M2.09M
Gross Profit2.05M17.79M13.17M15.93M5.74M
Gross Margin30.3%59.8%42.1%85.1%73.3%
Research & Development43.81M77.81M98.38M33.59M52.65M
Selling, General & Admin23.62M25.13M31.1M22.2M21.97M
Operating Expenses91.77M107.65M110.53M157.86M82.11M
Depreciation & Amortization923K797K863K807K454K
EBITDA(64.46M)(84.36M)(115.45M)(51.72M)(64.47M)
EBITDA Margin-953.4%-283.5%-369.5%-276.3%-823.8%
Operating Income(89.72M)(89.85M)(97.36M)(141.93M)(76.38M)
Operating Margin-1327.1%-302.0%-311.6%-758.2%-975.9%
Interest Income0007.95M7.64M
Interest Expense00000
Other Income / Expenses(1.14M)2.95M8.51M9.87M11.45M
Income Before Tax(90.87M)(86.91M)(88.85M)(132.07M)(64.92M)
Pre-Tax Margin-1344.0%-292.1%-284.3%-705.5%-829.6%
Income Tax Expense00(367K)00
Net Income(90.87M)(86.91M)(88.48M)(132.07M)(64.92M)
Net Margin-1344.0%-292.1%-283.1%-705.5%-829.6%
EPS (Basic)(1.60)(1.33)(1.27)(1.71)(0.53)
EPS (Diluted)(1.60)(1.33)(1.27)(1.71)(0.53)
Weighted Avg Shares56.73M65.21M69.81M77.3M122.66M
Weighted Avg Shares (Diluted)56.73M65.21M69.81M77.3M122.66M

Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.